CoChat
Sign Up
Cited by 205Coenzyme Q10 studies and effectsParkinson's Disease Mechanisms and TreatmentsNeurological diseases and metabolism

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

Randomized, Double-blind, Placebo-Controlled Trial on Symptomatic Effects of Coenzyme Q10 in Parkinson Disease

Storch, Alexander·2007·Archives of Neurology
DOI 10.1001/archneur.64.7.nct60005
Open this paper in CoChat — free account

Abstract

BACKGROUND: Major hallmarks in the pathophysiology of Parkinson disease are cellular energy depletion and oxidative stress leading to cellular dysfunction and death. Coenzyme Q(10) (CoQ(10)) is an electron acceptor bridging mitochondrial complexes I and II/III and a potent antioxidant that consistently partially recovers the function of dopaminergic neurons. OBJECTIVE: To determine whether nanoparticular CoQ(10) is safe and displays symptomatic effects in patients with midstage Parkinson disease without motor fluctuations. DESIGN: Multicenter, randomized, double-blind, placebo-controlled, stratified, parallel-group, single-dose trial. SETTING: Academic and nonacademic movement disorder clinics. PATIENTS: One hundred thirty-one patients with Parkinson disease without motor fluctuations and a stable antiparkinsonian treatment. Intervention Random assignment to placebo or nanoparticular CoQ(10) (100 mg 3 times a day) for a treatment period of 3 months. Stratification criterion was levodopa treatment. MAIN OUTCOME MEASURE: The subjects underwent evaluation with the Unified Parkinson's Disease Rating Scale (UPDRS) at each visit on a monthly basis. The primary outcome variable was the change of the sum score of the UPDRS parts II and III between the baseline and 3-month visits. RESULTS: One hundred thirty-one subjects were randomized according to the protocol. The mean changes of the sum UPDRS parts II/III score were -3.69 for the placebo group and -3.33 for the CoQ(10) group (P = .82). Statistical analysis according to the stratification did not result in significant changes of the primary outcome variable. No secondary outcome measure showed a significant change between the placebo group and the CoQ(10) group. The frequency and quality of adverse events were similar in both treatment groups. CONCLUSIONS: Nanoparticular CoQ(10) at a dosage of 300 mg/d is safe and well tolerated and leads to plasma levels similar to 1200 mg/d of standard formulations. Add-on CoQ(10) does not display symptomatic effects in midstage Parkinson disease.

Overview

Integrity signals

Registry

Crossref · 10.1001/archneur.64.7.nct60005

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Show all 29 references

Cited by

Sorted by citations

Items 201–204 of 204

Related

See all

Metadata

Authors
Storch, A.
Affiliations
Technische Universität Dresden (DE)
Corresponding author
Storch, Alexander
ORCID
Storch, Alexander
Venue
Archives of Neurology
Publisher
American Medical Association (AMA)
Published
2007-07-01
Volume
64
Issue
7
Pages
938
ISSN
0003-9942 (ISSN-L)
DOI
10.1001/archneur.64.7.nct60005
OpenAlex
W2144592798
Cited by
205
References
29
Citations by year
2026: 3 · 2025: 8 · 2024: 8 · 2023: 5 · 2022: 7 · 2021: 5 · 2020: 8 · 2019: 5 · 2018: 7 · 2017: 9 · 2016: 7 · 2015: 8 · 2014: 14 · 2013: 16 · 2012: 21
FWCI
8.30
Type
journal article
Language
en
Open access
closed
Locations
  • Archives of Neurology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Coenzyme Q10 studies and effects
  • Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
  • Life Sciences › Neuroscience › Neurology › Neurological diseases and metabolism
Keywords
coenzyme Q10, Parkinson's disease, levodopa, dopaminergic neurons, oxidative stress, mitochondrial bioenergetics, antioxidants, adjunctive therapy, drug safety and tolerability, Unified Parkinson's Disease Rating Scale
MeSH terms
Adult, Aged, Antioxidants, Coenzymes, Dopamine, Dose-Response Relationship, Drug, Double-Blind Method, Drug Administration Schedule, Energy Metabolism, Female, Humans, Levodopa, Male, Middle Aged, Neurons, Parkinson Disease, Placebos, Substantia Nigra, Ubiquinone, Vitamins, Treatment Outcome, Oxidative Stress, Cell Respiration

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review